Skip to content

Scailyte and Volv Global announce strategic partnership

scailyte volv global strategic partnership

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Artificial Intelligence (AI)-driven biomarker discovery innovators Scailyte and Volv Global, today announced a strategic partnership to develop a patient identification and diagnostic platform for rare diseases. 

The companies join their unprecedented expertise in data analysis: Volv Global identifies digital disease biomarkers by screening patient electronic health records (EHRs) with a unique automated disease learning platform, inTrigue and Scailyte leverages a best-in-class single-cell data analysis platform, ScaiVision, to identify and validate disease-specific molecular biomarkers. 

Through the joint venture, Volv Global will identify potential patients with rare or difficult to diagnose diseases, who can then be enrolled in molecular biomarker discovery studies led by Scailyte and clinical key opinion leaders in the disease area. 

The benefits of these joint efforts will be multifaceted: undiagnosed or misdiagnosed patients will be treated appropriately much earlier, clinicians will have tools for an informed diagnosis and pharmaceutical companies will be able to provide therapies to the target population with high response rates.

Peter Nestorov, PhD, CEO of Scailyte commented: “One of the key challenges with oncological and immunological diseases is their biological complexity. So to diagnose these diseases accurately and stratify the patients, a multi-parametric approach is needed – one that combines molecular readouts with clinical data and a smart algorithm to support clinicians in their decisions. I am excited that the Volv-Scailyte partnership addresses this major clinical need in a holistic way and has the potential to make a difference for millions of undiagnosed or misdiagnosed patients.”

Christopher Rudolf, CEO of Volv Global added: “We are learning more and more about rare diseases, for example, that what might once have been thought of as a single rare disease is actually multiple rare diseases that have been classified under a single category. This is why so many patients remain undiagnosed or misdiagnosed. The partnership between Vovlv and Scailyte has the potential to dramatically improve the journey to diagnosis and treatment for patients. The synergies between our two companies offer an important value proposition to patients, clinicians and pharma companies.”

About Scailyte

Scailyte AG is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to precise diagnosis and prediction of therapy response. Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays. For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

About Volv Global

Volv is a Swiss, an AI and applied data science company based in Lausanne that produces solutions to address key critical issues in Healthcare for today and tomorrow. We develop differentiated Artificial Intelligence methodologies addressing a defined set of problems in healthcare, and have solutions that are targeted on rare diseases, personalised medicines, and difficult-to-diagnose diseases with the product inTrigue. Volv also focus on cognitive disorders with inCognita, and chronic disease management solutions with inVerse. With unique tools, including some that are focused on finding weak signals in sparse, unstructured and structured data, Volv has a unique position in the Artificial Intelligence landscape. This allows us to focus on tangible economic and healthcare outcomes by differentiating patient cohorts and symptoms in a novel way that is required for the next generation of healthcare and the change in population dynamics that we see evolving. Volv’s toolsets are repeatable solutions that can fit into any data environment and allow rapid return on investment for our customers, building to longer term strategic partnerships. For more information, visit Volv Global website: www.volv.global.

Recent News

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

Recent News

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Recent News

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

Recent News

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

Recent News

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News

01 /04

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

02 /04

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

03 /04

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

04 /04

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News